

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

- 1 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

- 3 **New Drug for Chronic Myeloid Leukemia Might Stimulate the Market**
Martin C. Müller
See related article, p. 70
- 5 **Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy**
Joyce K. Hwang, Neeraj Agarwal, James Brugarolas, and Tian Zhang
See related article, p. 78
- 8 **Age is in the Eye of the Beholder: Distinguishing Molecular Signatures in Early-onset Pancreatic Adenocarcinomas**
Emil Lou
See related article, p. 246

CCR Perspectives in Regulatory Science and Policy

- 11 **U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program**
R. Angelo de Claro, Jennifer J. Gao, Tamy Kim, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, and Richard Pazdur

Review

- 15 **Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma**
Francesco Maura, Ola Landgren, and Gareth J. Morgan

Perspectives

- 24 **Similarities in Risk for COVID-19 and Cancer Disparities**
Lisa A. Newman, Robert A. Winn, and John M. Carethers

Special Report

- 28 **The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)**
A C Vivian Chua, Jane Mattei, Anna Han, Lauren Johnston, Kyleigh LiPira, Sara M. Selig, Richard D. Carvajal, Andrew E. Aplin, and Sapna P. Patel

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

- 34 **Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib**
A C Ezra Y. Rosen, Melissa L. Johnson, Sarah E. Clifford, Romel Somwar, Jennifer F. Kherani, Jieun Son, Arrien A. Bertram, Monika A. Davare, Eric Gladstone, Elena V. Ivanova, Dahlia N. Henry, Elaine M. Kelley, Mika Lin, Marina S.D. Milan, Binoj C. Nair, Elizabeth A. Olek, Jenna E. Scanlon, Morana Vojnic, Kevin Ebata, Jaclyn F. Hechtman, Bob T. Li, Lynette M. Sholl, Barry S. Taylor, Marc Ladanyi, Pasi A. Jänne, S. Michael Rothenberg, Alexander Drilon, and Geoffrey R. Oxnard

CLINICAL TRIALS: TARGETED THERAPY

- 43 **Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma**
A C Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Jianming Ying, Weiqing Han, Changlu Hu, Yun Ling, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Aiping Zhou, and Jun Guo

TABLE OF CONTENTS

- 52 Expanded Low Allele Frequency *RAS* and *BRAF* V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial**
Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, and Scott Kopetz

- 60 Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia**

A C Joshua F. Zeidner, Daniel J. Lee, Mark Frattini, Gil D. Fine, Judy Costas, Kathryn Kolibaba, Stephen P. Anthony, David Bearss, and B. Douglas Smith

- 70 Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESnd Study**
Li Zhang, Li Meng, Bingcheng Liu, Yanli Zhang, Huanling Zhu, Jiuwei Cui, Aining Sun, Yu Hu, Jie Jin, Hao Jiang, Xi Zhang, Yan Li, Li Liu, Wanggang Zhang, Xiaoli Liu, Jian Gu, Jianhui Qiao, Guifang Ouyang, Xin Liu, Jianmin Luo, Ming Jiang, Xiaobao Xie, Jianyong Li, Chunting Zhao, Mei Zhang, Tonghua Yang, and Jianxiang Wang

See related commentary, p. 3

CLINICAL TRIALS: IMMUNOTHERAPY

- 78 Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma**
Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean-Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jeronimo R. Rodriguez-Cid, Sumanta K. Pal, Andre M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, and Brian I. Rini
- See related commentary, p. 5

- 87 Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity**
Shipra Gandhi, Manu R. Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen, Cheryl Allen, Joseph D. Tario, Paul K. Wallace, Carlos D. Ceden, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J. Drabick, Mark J. Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A. Repasky, and Marc S. Ernstoff

- 96 Intratumoral Injection of *Clostridium novyi*-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors**

Filip Janku, Halle Huihong Zhang, Abdulmohammad Pezeshki, Sanjay Goel, Ravi Murthy, Andrea Wang-Gillam, Dale R. Shepard, Thorunn Helgason, Tyler Masters, David S. Hong, Sarina A. Piha-Paul, Daniel D. Karp, Mark Klang, Steven Y. Huang, Divya Sakamuri, Anjali Raina, Jean Torrisi, Stephen B. Solomon, Alice Weissfeld, Ernest Trevino, Gary DeCrescenzo, Amanda Collins, Maria Miller, Jennifer L. Salstrom, Ronald L. Korn, Linping Zhang, Saurabh Saha, Alexey A. Leontovich, David Tung, Brent Kreider, Mary Varterasian, Khashayarsha Khazaie, and Mrinal M. Gounder

PRECISION MEDICINE AND IMAGING

- 107 Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen**
Yurina Ogawa, Yohei Masugi, Tokiya Abe, Ken Yamazaki, Akihisa Ueno, Yoko Fujii-Nishimura, Shutaro Hori, Hiroshi Yagi, Yuta Abe, Minoru Kitago, and Michiie Sakamoto

- 120 Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting**
A C Jeffrey S. Morris, Rajyalakshmi Luthra, Yusha Liu, Dzifa Y. Duose, Wonyul Lee, Neelima G. Reddy, Justin Windham, Huiqin Chen, Zhimin Tong, Baili Zhang, Wei Wei, Manyam Ganiraju, Bradley M. Broom, Hector A. Alvarez, Alicia Mejia, Omkara Veeranki, Mark J. Routbort, Van K. Morris, Michael J. Overman, David Menter, Riham Katkhuda, Ignacio I. Wistuba, Jennifer S. Davis, Scott Kopetz, and Dipen M. Maru

- 131 Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma**
A C Paul Johannet, Nicolas Coudray, Douglas M. Donnelly, George Jour, Irineu Illa-Bochaca, Yuhe Xia, Douglas B. Johnson, Lee Wheless, James R. Patrinely, Sofia Nomikou, David L. Rimm, Anna C. Pavlick, Jeffrey S. Weber, Judy Zhong, Aristotelis Tsirigos, and Iman Osman

- 141 Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence**
A C Hao Xie, Douglas W. Mahoney, Patrick H. Foote, Kelli N. Burger, Karen A. Doering, William R. Taylor, Sara S. Then, Xiaoming Cao, Maria McGlinch, Calise K. Berger, Tsung-Teh Wu, Joleen M. Hubbard, Hatim T. Allawi, Michael W. Kaiser, Graham P. Lidgard, David A. Ahlquist, and John B. Kisiel

TABLE OF CONTENTS

- 150** **Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics**
James T. Topham, Joanna M. Karasinska, Michael K.C. Lee, Veronika Csizmok, Laura M. Williamson, Gun Ho Jang, Robert E. Denroche, Erica S. Tsang, Steve E. Kalloger, Hui-li Wong, Grainne M. O’Kane, Richard A. Moore, Andrew J. Mungall, Faiyaz Notta, Jonathan M. Loree, Julie M. Wilson, Oliver Bathe, Patricia A. Tang, Rachel Goodwin, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, Steven J.M. Jones, Daniel J. Renouf, and David F. Schaeffer
- 158** **International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia**
Maximilian Schönung, Julia Meyer, Peter Nöllke, Adam B. Olshen, Mark Hartmann, Norihiro Murakami, Manabu Wakamatsu, Yusuke Okuno, Christoph Plass, Mignon L. Loh, Charlotte M. Niemeyer, Hideki Muramatsu, Christian Flotho, Elliot Stieglitz, and Daniel B. Lipka
- 169** **TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas**
Koushik Muralidharan, Anudeep Yekula, Julia L. Small, Zachary S. Rosh, Keiko M. Kang, Lan Wang, Spencer Lau, Hui Zhang, Hakho Lee, Chetan Bettgowda, Michael R. Chicoine, Steven N. Kalkanis, Ganesh M. Shankar, Brian V. Nahed, William T. Curry, Pamela S. Jones, Daniel P. Cahill, Leonora Balaj, and Bob S. Carter
- 179** **MRI and ¹⁸FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial**
Hans-Georg Wirsching, Ulrich Roelcke, Jonathan Weller, Thomas Hundsberger, Andreas F. Hottinger, Roger von Moos, Francesca Caparrotti, Katrin Conen, Luca Remonda, Patrick Roth, Adrian Ochsenbein, Ghazaleh Tabatabai, and Michael Weller
- 189** **Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs**
Nicola Colclough, Kan Chen, Peter Johnström, Nicole Strittmatter, Yumei Yan, Gail L. Wrigley, Magnus Schou, Richard Goodwin, Katarina Varnäs, Sally J. Adua, Minghui Zhao, Don X. Nguyen, Gareth Maglennon, Peter Barton, James Atkinson, Lin Zhang, Annika Janefeldt, Joanne Wilson, Aaron Smith, Akihiro Takano, Ryosuke Arakawa, Mikhail Kondrashov, Jonas Malmquist, Evgeny Revunov, Ana Vazquez-Romero, Mohammad Mahdi Moein, Albert D. Windhorst, Natasha A. Karp, M. Raymond V. Finlay, Richard A. Ward, James W.T. Yates, Paul D. Smith, Lars Farde, Zack Cheng, and Darren A.E. Cross
- 202** **Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors**
A C Alexandra Pender, Emma Titmuss, Erin D. Pleasance, Kevin Y. Fan, Hillary Pearson, Scott D. Brown, Cameron J. Grisdale, James T. Topham, Yaoqing Shen, Melika Bonakdar, Gregory A. Taylor, Laura M. Williamson, Karen L. Mungall, Eric Chuah, Andrew J. Mungall, Richard A. Moore, Jean-Michel Lavoie, Stephen Yip, Howard Lim, Daniel J. Renouf, Sophie Sun, Robert A. Holt, Steven J.M. Jones, Marco A. Marra, and Janessa Laskin
- 213** **A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma**
Santiago Demajo, Robert Albero, Guillem Clot, Giancarlo Castellano, Alba Navarro, Cristina Capdevila, Anna Enjuanes, Ferran Nadeu, Eva Giné, Magda Pinyol, Elaine S. Jaffe, German Ott, Louis M. Staudt, Andreas Rosenwald, David W. Scott, Lisa M. Rimsza, Armando López-Guillermo, Sílvia Bea, Elias Campo, and Pedro Jares
- 226** **Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA**
ChongFeng Gao, Luke Wisniewski, Ying Liu, Ben Staal, Ian Beddows, Dennis Plenker, Mohammed Aldakkak, Johnathan Hall, Daniel Barnett, Mirna Kheir Gouda, Peter Allen, Richard Drake, Amer Zureikat, Ying Huang, Douglas Evans, Aatur Singhi, Randall E. Brand, David A. Tuveson, Susan Tsai, and Brian B. Haab
- 237** **Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma**
Ji Eun Park, Ho Sung Kim, NakYoung Kim, Seo Young Park, Young-Hoon Kim, and Jeong Hoon Kim
- 246** **Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?**
Erica S. Tsang, James T. Topham, Joanna M. Karasinska, Michael K.C. Lee, Laura M. Williamson, Shehara Mendis, Robert E. Denroche, Gun Ho Jang, Steve E. Kalloger, Richard A. Moore, Andrew J. Mungall, Oliver F. Bathe, Patricia A. Tang, Faiyaz Notta, Julie M. Wilson, Janessa Laskin, Grainne M. O’Kane, Jennifer J. Knox, Rachel A. Goodwin, Jonathan M. Loree, Steven J.M. Jones, Marco A. Marra, Steven Gallinger, David F. Schaeffer, and Daniel J. Renouf
See related commentary, p. 8

TABLE OF CONTENTS

- 255** **An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy**
Yun Wang, Yan-yu Cai, Tobias Herold, Run-cong Nie, Yu Zhang, Robert Peter Gale, Klaus H. Metzeler, Yun Zeng, Shun-qing Wang, Xue-yi Pan, Tong-hua Yang, Yuan-bin Wu, Qing Zhang, Zhi-jun Wuxiao, Xin Du, Zhi-wei Liang, Yong-zhong Su, Jing-bo Xu, Yong-qing Wang, Ze-lin Liu, Jian-wei Wu, Xiong Zhang, Bing-yi Wu, Ruo-zhi Xiao, San-bin Wang, Jin-yuan Li, Pei-dong Chi, Qian-yi Zhang, Si-liang Chen, Zhe-yuan Qin, Xin-mei Zhang, Na Zhong, Wolfgang Hiddemann, Qi-fa Liu, Bei Zhang, and Yang Liang

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 267** **Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)**
Federico Innocenti, Alexander B. Sibley, Sushant A. Patil, Amy S. Etheridge, Chen Jiang, Fang-Shu Ou, Stefanie D. Howell, Sarah J. Plummer, Graham Casey, Monica M. Bertagnolli, Howard L. McLeod, James T. Auman, Charles D. Blanke, Yoichi Furukawa, Alan P. Venook, Michiaki Kubo, Heinz-Josef Lenz, Joel S. Parker, Mark J. Ratain, and Kouros Owzar
- 276** **Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma**
J. Bryan Iorgulescu, Prafulla C. Gokhale, Maria C. Speranza, Benjamin K. Eschle, Michael J. Poitras, Margaret K. Wilkens, Kara M. Soroko, Chhayheng Chhoeu, Aine Knott, Yan Gao, Mary Jane Lim-Fat, Gregory J. Baker, Dennis M. Bonal, Quang-Dé Nguyen, Gareth R. L. Grant, Keith L. Ligon, Peter K. Sorger, E. Antonio Chiocca, Ana C. Anderson, Paul T. Kirschmeier, Arlene H. Sharpe, Gordon J. Freeman, and David A. Reardon
- 288** **In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer**
A C Sudhir B. Malla, David J. Fisher, Enric Domingo, Andrew Blake, Sylvana Hassanieh, Keara L. Redmond, Susan D. Richman, Michael Youdell, Steven M. Walker, Gemma E. Logan, Aikaterina Chatzipli, Raheleh Amirkhah, Matthew P. Humphries, Stephanie G. Craig, Ultan McDermott, Matthew T. Seymour, Dion G. Morton, Philip Quirke, Nicholas P. West, Manuel Salto-Tellez, Richard D. Kennedy, Patrick G. Johnston, Ian Tomlinson, Viktor H. Koelzer, Letitia Campo, Richard S. Kaplan, Daniel B. Longley, Mark Lawler, Timothy S. Maughan, Louise C. Brown, and Philip D. Dunne, on behalf of the S:CORT consortium

- 301** **Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study**
A C Jiaolin Zhou, Changxi Wang, Guole Lin, Yi Xiao, Wenzhuo Jia, Gang Xiao, Qian Liu, Bin Wu, Aiwen Wu, Huizhong Qiu, Fuquan Zhang, Ke Hu, Huadan Xue, Zhanlong Shen, Zhenjun Wang, Jiagang Han, Beizhan Niu, Yaping Xu, Zicheng Yu, and Ling Yang
- 311** **Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR⁺ Early-stage Breast Cancer for 10 Years of Endocrine Therapy**
A C Iris Noordhoek, Kai Treuner, Hein Putter, Yi Zhang, Jenna Wong, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Cornelis J.H. van de Velde, Catherine A. Schnabel, and Gerrit-Jan Liefers
- 320** **Comparative Genomics Reveals Distinct Immunologic Pathways in African American Men with Prostate Cancer**
Shivanshu Awasthi, Anders Berglund, Julieta Abraham-Miranda, Robert J. Rounbehler, Kevin Kensler, Amparo Serna, Adriana Vidal, Sungyong You, Michael R. Freeman, Elai Davicioni, Yang Liu, R. Jeffrey Karnes, Eric A. Klein, Robert B. Den, Bruce J. Trock, Joshua D. Campbell, David J. Einstein, Raavi Gupta, Steven Balk, Priti Lal, Jong Y. Park, John L. Cleveland, Timothy R. Rebbeck, Stephen J. Freedland, and Kosj Yamoah
- 330** **An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma**
Yue Chen, Zhi-Yong Li, Guan-Qun Zhou, and Ying Sun
- 342** **Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling**
Chen Liu, Hengyu Lu, Hongyun Wang, Alice Loo, Xiamei Zhang, Guizhi Yang, Colleen Kowal, Scott Delach, Ye Wang, Silvia Goldoni, William D. Hastings, Karrie Wong, Hui Gao, Matthew J. Meyer, Susan E. Moody, Matthew J. LaMarche, Jeffrey A. Engelman, Juliet A. Williams, Peter S. Hammerman, Tinya J. Abrams, Morvarid Mohseni, Giordano Caponigro, and Huai-Xiang Hao

LETTERS TO THE EDITOR

- 355** **Drug-Radiotherapy Combination Trial Developments—Letter**
Joseph R. Evans, Kyle C. Cuneo, and Theodore S. Lawrence
- 356** **Drug-Radiotherapy Combination Trial Developments—Response**
Eric Deutsch, Cyrus Chargari, Ralph R. Weichselbaum, and Antonin Levy

TABLE OF CONTENTS

CORRECTIONS

- 357** **Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial**
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren S. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirilan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Y. Jo, Matthew D. Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, and Douglas R. Adkins

- 358** **Correction: Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma**

Changqing Xie, Austin G. Duffy, Gagandeep Brar, Suzanne Fioravanti, Donna Mabry-Hrones, Melissa Walker, Cecilia Monge Bonilla, Bradford J. Wood, Deborah E. Citrin, Elizabeth M. Gil Ramirez, Freddy E. Escorcía, Bernadette Redd, Jonathan M. Hernandez, Jeremy L. Davis, Billel Gasmi, David Kleiner, Seth M. Steinberg, Jennifer C. Jones, and Tim F. Greten


- 359** **Acknowledgment to Reviewers**

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a tissue section from a patient with pancreatic ductal adenocarcinoma. Multiplex fluorescent immunohistochemistry of FAP (fibroblast activation protein alpha, green) and ACTA2 (alpha smooth muscle action, magenta) visualizes mutually exclusive fibroblast subpopulations. For details, see the article by Ogawa and colleagues on page 107 of this issue.



Clinical Cancer Research

27 (1)

Clin Cancer Res 2021;27:1-367.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/27/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.